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Health) was conducted. SourceLX contains linked prescription
and diagnosis claims for $35 million patients with insurance
coverage from a variety of sources. Data were screened to identify
records between December 1, 2005 and November 30, 2006 with
a medical claim for BoNT-A (UB92 or CMS1500) and an ICD-9
diagnosis for headache or migraine on the same claim.RESULTS:
In the 12-month analysis period, approximately 2.88 million
people visited a physician for headache or migraine. Only 1754
patients (0.06%) received treatmentwith BoNT-A; the vastmajor-
ity (80%) had a speciﬁc diagnosis of migraine, not a general
diagnosis of headache. BoNT A recipients were between 40–59
years of age (46%) and most were female (83.1%); BoNT-A
treatment was most often (84%) prescribed by a neurologist.
Fewer (26%) BoNT-A treated users compared to non- BoNT-A
users (52%) were using more than one medication to treat head-
ache or migraine symptoms. In BoNT-A users, the use of combi-
nation pain medication (2 of the following: opioid analgesic,
non-narcotic analgesic, topical anesthetic, NSAID or synthetic
narcotic) was signiﬁcantly reduced in the 90 days after BoNT-A
treatment (p < 0.01). CONCLUSION: BoNT-A treated users are
mostly migraine sufferers. BoNT A treated patients required less
pain medication. Further research needs to be conducted to deter-
mine whether BoNT-A impacts overall treatment costs.
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OBJECTIVE: To summarize clinical rates in treating neuropathic
pain of three drug classes: tricyclic antidepressants (TCAs),
serotonin-norepinephrine reuptake inhibitors (SNRIs), and anti-
convulsants (ACs). METHODS: Patients included adults diag-
nosedwith neuropathic pain experienced >3months.We accepted
double-blinded randomized clinical trials using any drug within
these classes against placebo/active comparator. Outcomes re-
ported were pain score changes on a visual analog scale (VAS),
partial response and response (30% and 50% reduction, respec-
tively), and ADR dropout rates. Two independent reviewers
searchedMedline, Embase, and Cochrane databases (inception to
2007), plus references from retrieved articles. Discrepancies were
resolved by consensus (adjudication by a third reviewer). Data
were extracted/veriﬁed similarly. Quality was similarly assessed
using Jadad’s method. Homogeneity of effects was determined
using Chi-square and I-square. Data were combined using a
random-effects model. RESULTS: From 115 articles, 84 were
excluded (45 inappropriate drugs, 20 inappropriate patients, 12
unacceptable designs, ﬁve insufﬁcient outcome data, one dupli-
cate, and one not located), leaving 28. Thirteen studies (N = 1257)
evaluated ACs (gabapentin, pregabalin), ﬁve SNRIs (N = 781),
and ten TCAs (N = 249). One evaluated both ACs and TCAs.
Quality was 81%  21% overall. Weighted mean baseline-
endpoint VAS differences were: TCAs = 1.8 (95%CI = 1.2–2.4;
13 studies, N = 249), SNRIs = 2.7 (95%CI = 2.4–3.0; 10 studies,
N = 781), and ACs = 2.4 2 were signiﬁcant and I2 were c
(95%CI = 2.0–2.8; 20 studies, N = 1257). All 63%–90%, indi-
cating heterogeneity. For partial response, we analyzed 17 study
arms (N = 1439), nine involving ACs (n = 870), four examining
SNRIs (n = 458), and four that studied TCAs (n = 111). Rates
were: SNRIs = 66.0%  2.2%, ACs = 54.5%  3.7%, and
TCAs = 49.2%  6.6%. For full response, 27 study arms were
summarized: SNRIs = 45.9%  2.3%, ACs = 36.3%  3.2%,
and TCAs = 32.3%  4.4%. ADR dropout rates were:
ACs = 12.3%  1.8% (N = 1,259), SNRIs = 12.0%  2.3%
(N = 732), TCAs = 11.7%  2.7% (N = 267). CONCLUSION:
For all success measures, SNRIs rates were highest, then ACs, then
TCAs. Dropout rates were comparable among drug classes.
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OBJECTIVE: To use clinician reported data pre- and post-
operative in bariatric surgery patients to create an algorithm for
the development of a standardized tool, for use by bariatric
surgeons within a conﬁdence interval, to determine the
maximum weight loss threshold from roux en y surgery by the
third physician visit. METHODS: Retrospective database
analysis (2000–2007) of empirical clinical data, pre- and
post-operative, for bariatric patients in Western New York. A
multivariate model examined the relationship between % excess
body weight lost (BWL) at the ﬁrst three post-operative visits and
% BWL at the sixth post-operative visit (V6), using SAS 9.1.
Percent excess BWL was plotted vs. days elapsed from surgery.
179 obese adults (women = 155, 86.6%) received gastric bypass
surgery, mean BMI = 53, (SD = 9.6), mean excess body weight at
time of procedure = 185 lbs (SD = 65.3). RESULTS: Outcomes
were available for 158 patients (women = 137, 86.7%) at V6
(mean = 707 days), mean BMI = 35.2 (SD = 7.7), women = 34.7
vs. men = 38.1. Mean % excess BWL at V6 was 60%
(SD = 18%). Women had more BWL than men (61% vs. 55%).
For females, BWL was maximized at 870 days post-operation,
the equation ﬁt for males did not yield an absolute maximum,
leveling off at 740 days (monthly change rate < 0.5%/month).
Our model included linear and non-linear components to corre-
late the relationship between the total % excess BWL at V6 and
% excess BWL at the ﬁrst three visits. All variables, except BWL
at the second visit, were statistically signiﬁcant. The algorithm
had a predictive accuracy of 94%. CONCLUSION: The excess
BWL at the third visit is predictive of the ﬁnal excess BWL,
following surgery. Gender and initial BMI displayed signiﬁcant
relationships with ﬁnal weight loss. The algorithm derived from
this sample will support the development of a standardized tool
to assist physicians in their post-operative prognosis of gastric
bypass patients.
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OBJECTIVE: To assess the ability of BTX-A injections to lower
migraine frequency in chronic sufferers. METHODS: Two re-
viewers independently searched PubMed, Google Scholar and
Cochrane Library to locate randomized, double-blind, placebo-
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